Rensselaer investigator awarded $1.6 million grant to study the mechanics of mitosis to fight cancer

It is a scary fact that one in two women and one in three men in the United States will develop some form of cancer in their lifetime. One of the hallmarks of many cancers is the occurrence of errors during the cell division process called mitosis. Therefore, critical to enhancing treatments or perhaps even finding a cure for cancer and other diseases, is developing a better understanding of how mitosis works in both healthy and diseased cells.

Rensselaer Polytechnic Institute's Scott Forth, Ph.D., assistant professor of biological sciences and member of the Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies, has made understanding the cell's complicated mechanical tasks, such as those needed for mitosis, his life's work. Recently, he was awarded a $1.6 million grant over five years by the National Institutes of Health to further his research.

With this grant, Forth will explore the mechanical code that underlies the assembly and function of force-generating cytoskeletal networks, using mitosis as a model biological process. One way that cells prepare to divide into two is by duplicating their contents, including chromosomes. Cells then assemble their cytoskeletal networks to produce forces that physically segregate chromosomes into each of two new cells. Errors in this process are linked to cancer.

Though decades of research has identified a majority of the biological 'parts' that are involved, we still do not understand the mechanical rules that dictate how all of these tiny individual pieces work together as ensembles to accomplish goals like the reliable segregation of DNA into two new daughter cells."

Scott Forth, Ph.D., assistant professor of biological sciences and member of the Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies

Within the cytoskeleton are micron-scale microtubule networks that need both motor and non-motor proteins to move and organize filaments into proper, functional mechanical units that produce the forces needed to pull chromosomes apart. To better understand how they work, Forth will employ a variety of techniques such as biochemical reconstitution, single-molecule fluorescence microscopy, optical trapping, and live-cell imaging. Biochemical reconstitution employs purified proteins to mimic intracellular processes outside of the cell, and optical trapping is a method for measuring the tiny forces that proteins can generate. Fluorescence microscopy will be used at the same time to watch individual molecules respond to these forces, while live cell imaging will be performed to confirm these biophysical measurements in real dividing cells.

With this grant, Forth hopes to gain three new insights. First, his lab will determine the mechanical and functional differences between bridging fibers in metaphase, when chromosomes are first being properly centered within the cell, and the central spindle microtubule network in anaphase, when chromosomes are being pulled away from each other. Second, he will determine the molecular mechanisms that regulate how microtubule-associated proteins (MAPs) cluster to form novel cellular "building blocks," and decipher the functional role of MAP clusters in regulating microtubule organization. Third, his lab will determine how complexes of motor and non-motor MAPs collectively regulate microtubule organization during later stages of mitosis to help ensure proper division of the two cells.

"Dr. Forth's work in cellular physics informs our understanding of diseases, such as cancer, that occur when cell structures fail," said Curt Breneman, Ph.D., dean of Rensselaer's School of Science. "With this grant, Dr. Forth will gain new insights into molecular mysteries that may forge a path to the development of new diagnostics and treatments."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Off-the-shelf cancer vaccine shows promising results in patients with KRAS-mutated tumors